polidocanol and Liver-Neoplasms

To evaluate the efficacy of three endoscopic therapies of isolated gastric varices (IGV) with modified tissue adhesive.. A retrospective analysis was conducted with the clinical data of 73 IGV patients who were treated between January 2008 and December 2019 at Beijing Ditan Hospital. Patient clinical data on age, sex, etiology, biochemistry findings, Child-Pugh classification, the type of spontaneous shunt, preoperative bleeding history, and the presence or absence of liver cancer were collected. The three therapies evaluated were endoscopic intravenous injection of tissue glue combined with lauromacrogol, endoscopic clip-assisted intravenous injection of tissue glue combined with lauromacrogol, and endoscopic clip and LOOP-assisted intravenous injection of tissue glue combined with lauromacrogol. Their respective clinical treatment outcomes, including ectopic embolism rate, survival rate, rebleeding rate, amount of lauromacrogol and tissue glue used, the number of endoscopic clips used, and the number of times of the procedure the patient underwent, were evaluated.. In the patient baseline data, Child-Pugh grade, preoperative thrombus formation, and the presence or absence of liver cancer, showed significant difference between the three therapies (. The two endoscopic therapies of intravenous injection of modified tissue glue, one assisted by clip and the other assisted by clip and LOOP, can help reduce the number of procedures IGV patients undergo within one year.

Topics: Esophageal and Gastric Varices; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Polidocanol; Retrospective Studies; Tissue Adhesives

To evaluate the clinical safety and effectiveness of foam sclerotherapy using polidocanol for preoperative portal vein embolization (PVE) before hemihepatectomy of the liver.. From March 2006 to October 2008, foam sclerotherapy using polidocanol was performed in 16 patients (male-to-female ratio of 12:4, age range 48-75 years [mean 62]) for PVE. Patients were diagnosed with Klatskin tumor (n = 13), gallbladder (GB) cancer (n = 2), or hepatocellular carcinoma (HCC) (n = 1). The foam was composed of a 1:2:1 ratio of 3% polidocanol (Aethoxysklerol; Kreussler Pharma, Wiesbaden, Germany), room air, and contrast media (Xenetix 350; Guerbet, Aulnay-Sous-Bois, France). The total amount of polidocanol used (2 to 8 mL [mean 4.6]) varied according to the volume of the target portal vein. We calculated the volume of future liver remnant (FLR) before and after PVE and evaluated complications associated with the use of polidocanol foam sclerotherapy for PVE.. Technical success was achieved in all patients. All patients were comfortable throughout the procedure and did not experience pain during sclerotherapy. No periprocedural morbidity or mortality occurred. Patients underwent a liver dynamic computed tomography (CT) scan 2-4 weeks after PVE. FLR increased significantly after PVE using polidocanol foam from 19.3% (range 16-35%) before PVE to 27.8% (range 23-42%) after PVE (p = 0.001). All patients were operable for hemihepatectomy of the liver and achieved effective resection.. Foam sclerotherapy using polidocanol is clinically safe and effective for preoperative PVE.

Topics: Aged; Angiography; Contrast Media; Embolization, Therapeutic; Female; Humans; Imaging, Three-Dimensional; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Portal Vein; Radiographic Image Interpretation, Computer-Assisted; Sclerosing Solutions; Sclerotherapy; Tomography, X-Ray Computed; Treatment Outcome

Hybrid liposomes (HLs) composed of vesicular and micellar surfactants have inhibitory effects on the growth of tumor cells in vitro and in vivo. Successful clinical chemotherapy with drug-free HLs to patient with lymphoma has been reported after approval by the Committe of Bioethics. However, the therapeutic effects of HLs on the metastasis of colon carcinoma cells have not yet been elucidated. In this study, the therapeutic effects of HLs composed of L-alpha-dimyristoylphosphatidylcholine (DMPC) and polyoxyethylene (23) dodecyl ether [C(12)(EO)(23)] on the metastasis of colon carcinoma (Colon26) cells were examined in vivo. Marked high therapeutic effects were obtained in the hepatic metastasis mice model after the treatment with HLs. Furthermore, optical microscopic analysis indicated that HLs could induce the apoptosis of colon carcinoma cells in vivo. No toxicity was observed in the hepatic metastasis mice model after intravenously injecting HLs. Therapeutic effects along with the induction of apoptosis by HLs without any drugs on hepatic metastasis were revealed on the basis of optical microscopic analysis for the first time in vivo.

Topics: Animals; Apoptosis; Carcinoma; Colonic Neoplasms; Dimyristoylphosphatidylcholine; Disease Models, Animal; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Liposomes; Liver Neoplasms; Mice; Mice, Inbred BALB C; Polidocanol; Polyethylene Glycols

To construct a liposomal liver targeting delivery system by adding soybean-derived sterylglucoside (SG) to the cationic liposomes.. The physico-chemical properties of SG modified cationic lipsomes were investigated using fluorescein sodium (FS) as a model drug, as well as the interaction of SG modified liposomes with HepG2 2. 2. 15 cells in the point of involvement of asialoglycoprotein receptor (ASGP-R) mediated transfection. Liver targeting of modified cationic liposomes were also investigated using liver perfusing technique, and hepatocytes and non-hepatocytes were separated and examined after perfusing.. All the formula yielded high incorporation efficiency (83.12% - 91.74%), small particle size (93.0 - 124.4 nm). The zeta potential of blank liposomes all showed positive values. The transfection efficiency of FS entrapped in SG-liposomes with HepG2 2.2. 15 was significantly higher than that of liposomes without modification. The transfection of SG-liposomes were reduced significantly by the 20/30 mmol galactose as a competitor of ASGP-R. All the cationic liposomes showed high level of liver uptake of FS. Compared with the uptake of non-hepatocytes of each respectively, only SG/Brij-35 liposomes showed difference in FS uptake by hepatocytes (P < 0.05).. It showed that SG/Brij-35 modified cationic liposomes are potentially useful drug carrier to liver but may be affected by different modification.

Topics: Animals; Carcinoma, Hepatocellular; Cations; Cell Line, Tumor; Cholestenes; Drug Delivery Systems; Galactose; Humans; Liposomes; Liver; Liver Neoplasms; Male; Particle Size; Polidocanol; Polyethylene Glycols; Rats; Transfection

Between April 1984 and October 1988, 10 patients with hepatocellular carcinoma who bled from esophageal varices were included in a polidocanol sclerotherapy program, after the cessation of bleeding. Sixty cirrhotic patients without hepatocellular carcinoma were included as controls in the same sclerotherapy program for the same period. According to Okuda's classification, 1 patient was grade I, and 9 were grade II. At 1 year, 41 percent of patients with hepatocellular carcinoma and 51 percent of controls had rebled (non significant). Varices were obliterated in 7 of 10 patients with hepatocellular carcinoma and in 41 of 60 control patients (non significant). At one year, treatment failed (rebleeding or death) in 54 percent patients with hepatocellular carcinoma and in 59 percent control patients (non significant). Child-Pugh's score was the principal prognostic factor for treatment failure in both groups. Portal vein thrombosis was found in 2 of the 3 hepatocellular carcinoma patients who rebled. Unlike propranolol, elective sclerotherapy treatment might be proposed to patients with hepatocellular carcinoma without portal thrombosis.

Topics: Aged; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis, Alcoholic; Liver Neoplasms; Male; Middle Aged; Polidocanol; Polyethylene Glycols; Prognosis; Recurrence; Sclerotherapy